Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes

Mohammed Abdelsaid, Maha Coucha, Adviye Ergul

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have shown that Goto-Kakizaki (GK) rats, a lean model of type 2 diabetes, develop significant cerebrovascular remodeling by the age of 18 weeks, which is characterized by increased media thickness and matrix deposition. Although early glycemic control prevents diabetes-mediated remodeling of the cerebrovasculature, whether the remodeling can be reversed is unknown. Given that angiotensin II type 1 receptor blockers reverse pathologic vascular remodeling and function independent of changes in blood pressure in other vascular beds, we hypothesized that azilsartan medoxomil, a new angiotensin II type 1 receptor blocker, is vasculoprotective by preventing and reversing cerebrovascular remodeling in diabetes. Control Wistar and diabetic GK rats (n = 6-8 per group) were treated with vehicle (water) or azilsartan medoxomil (3 mg/kg/d) from the age of 14 to 18 or 18 to 22 weeks before or after vascular remodeling is established, respectively. Blood glucose and blood pressure were monitored and middle cerebral artery structure and function were evaluated using pressurized arteriography. Blood glucose was higher in GK rats compared with Wistar rats. Azilsartan treatment lowered blood glucose in diabetic animals with no effect on blood pressure. Diabetic animals exhibited lower myogenic tone, increased wall thickness, and cross-sectional area compared with control group animals, which were corrected by azilsartan treatment when started at the onset of diabetes or later after vascular remodeling is established. Azilsartan medoxomil offers preventive and therapeutic vasculoprotection in diabetes-induced cerebrovascular remodeling and myogenic dysfunction and this is independent of blood pressure.

Original languageEnglish (US)
Pages (from-to)424-432
Number of pages9
JournalTranslational Research
Volume164
Issue number5
DOIs
StatePublished - Nov 1 2014

Fingerprint

Medical problems
Blood pressure
Rats
Blood Pressure
Angiotensin II Type 1 Receptor Blockers
Blood Glucose
Animals
Middle Cerebral Artery
Type 2 Diabetes Mellitus
Blood Vessels
Wistar Rats
Angiography
Control Groups
azilsartan medoxomil
Water
Vascular Remodeling
azilsartan
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Biochemistry, medical

Cite this

Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. / Abdelsaid, Mohammed; Coucha, Maha; Ergul, Adviye.

In: Translational Research, Vol. 164, No. 5, 01.11.2014, p. 424-432.

Research output: Contribution to journalArticle

Abdelsaid, Mohammed ; Coucha, Maha ; Ergul, Adviye. / Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. In: Translational Research. 2014 ; Vol. 164, No. 5. pp. 424-432.
@article{fff6021c602e49a5a6247414ea48111b,
title = "Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes",
abstract = "We have shown that Goto-Kakizaki (GK) rats, a lean model of type 2 diabetes, develop significant cerebrovascular remodeling by the age of 18 weeks, which is characterized by increased media thickness and matrix deposition. Although early glycemic control prevents diabetes-mediated remodeling of the cerebrovasculature, whether the remodeling can be reversed is unknown. Given that angiotensin II type 1 receptor blockers reverse pathologic vascular remodeling and function independent of changes in blood pressure in other vascular beds, we hypothesized that azilsartan medoxomil, a new angiotensin II type 1 receptor blocker, is vasculoprotective by preventing and reversing cerebrovascular remodeling in diabetes. Control Wistar and diabetic GK rats (n = 6-8 per group) were treated with vehicle (water) or azilsartan medoxomil (3 mg/kg/d) from the age of 14 to 18 or 18 to 22 weeks before or after vascular remodeling is established, respectively. Blood glucose and blood pressure were monitored and middle cerebral artery structure and function were evaluated using pressurized arteriography. Blood glucose was higher in GK rats compared with Wistar rats. Azilsartan treatment lowered blood glucose in diabetic animals with no effect on blood pressure. Diabetic animals exhibited lower myogenic tone, increased wall thickness, and cross-sectional area compared with control group animals, which were corrected by azilsartan treatment when started at the onset of diabetes or later after vascular remodeling is established. Azilsartan medoxomil offers preventive and therapeutic vasculoprotection in diabetes-induced cerebrovascular remodeling and myogenic dysfunction and this is independent of blood pressure.",
author = "Mohammed Abdelsaid and Maha Coucha and Adviye Ergul",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.trsl.2014.06.003",
language = "English (US)",
volume = "164",
pages = "424--432",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes

AU - Abdelsaid, Mohammed

AU - Coucha, Maha

AU - Ergul, Adviye

PY - 2014/11/1

Y1 - 2014/11/1

N2 - We have shown that Goto-Kakizaki (GK) rats, a lean model of type 2 diabetes, develop significant cerebrovascular remodeling by the age of 18 weeks, which is characterized by increased media thickness and matrix deposition. Although early glycemic control prevents diabetes-mediated remodeling of the cerebrovasculature, whether the remodeling can be reversed is unknown. Given that angiotensin II type 1 receptor blockers reverse pathologic vascular remodeling and function independent of changes in blood pressure in other vascular beds, we hypothesized that azilsartan medoxomil, a new angiotensin II type 1 receptor blocker, is vasculoprotective by preventing and reversing cerebrovascular remodeling in diabetes. Control Wistar and diabetic GK rats (n = 6-8 per group) were treated with vehicle (water) or azilsartan medoxomil (3 mg/kg/d) from the age of 14 to 18 or 18 to 22 weeks before or after vascular remodeling is established, respectively. Blood glucose and blood pressure were monitored and middle cerebral artery structure and function were evaluated using pressurized arteriography. Blood glucose was higher in GK rats compared with Wistar rats. Azilsartan treatment lowered blood glucose in diabetic animals with no effect on blood pressure. Diabetic animals exhibited lower myogenic tone, increased wall thickness, and cross-sectional area compared with control group animals, which were corrected by azilsartan treatment when started at the onset of diabetes or later after vascular remodeling is established. Azilsartan medoxomil offers preventive and therapeutic vasculoprotection in diabetes-induced cerebrovascular remodeling and myogenic dysfunction and this is independent of blood pressure.

AB - We have shown that Goto-Kakizaki (GK) rats, a lean model of type 2 diabetes, develop significant cerebrovascular remodeling by the age of 18 weeks, which is characterized by increased media thickness and matrix deposition. Although early glycemic control prevents diabetes-mediated remodeling of the cerebrovasculature, whether the remodeling can be reversed is unknown. Given that angiotensin II type 1 receptor blockers reverse pathologic vascular remodeling and function independent of changes in blood pressure in other vascular beds, we hypothesized that azilsartan medoxomil, a new angiotensin II type 1 receptor blocker, is vasculoprotective by preventing and reversing cerebrovascular remodeling in diabetes. Control Wistar and diabetic GK rats (n = 6-8 per group) were treated with vehicle (water) or azilsartan medoxomil (3 mg/kg/d) from the age of 14 to 18 or 18 to 22 weeks before or after vascular remodeling is established, respectively. Blood glucose and blood pressure were monitored and middle cerebral artery structure and function were evaluated using pressurized arteriography. Blood glucose was higher in GK rats compared with Wistar rats. Azilsartan treatment lowered blood glucose in diabetic animals with no effect on blood pressure. Diabetic animals exhibited lower myogenic tone, increased wall thickness, and cross-sectional area compared with control group animals, which were corrected by azilsartan treatment when started at the onset of diabetes or later after vascular remodeling is established. Azilsartan medoxomil offers preventive and therapeutic vasculoprotection in diabetes-induced cerebrovascular remodeling and myogenic dysfunction and this is independent of blood pressure.

UR - http://www.scopus.com/inward/record.url?scp=84908226836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908226836&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2014.06.003

DO - 10.1016/j.trsl.2014.06.003

M3 - Article

C2 - 24999268

AN - SCOPUS:84908226836

VL - 164

SP - 424

EP - 432

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 5

ER -